ETF Managers Group’s Relay Therapeutics RLAY Stock Holding History

ETF Managers Group’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,453	Closed	-$156K	–	729
2022 Q4	$156K	Buy	+10,453	New	+$200K	0.01%	485

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

ETF Managers Group's RLAY Position: Q1 2023 in Review

ETF Managers Group sold out of Relay Therapeutics (RLAY) in Q1 2023, closing a stake of 10,453 shares — an estimated $156K sold.

ETF Managers Group first reported a position in RLAY in Q4 2022 and held it in 1 quarter. The position peaked at $156K in Q4 2022. 157 funds tracked by Wall St. Rank hold RLAY as of Q1 2023.

ETF Managers Group reported no remaining Relay Therapeutics position as of Q1 2023 after selling out during the quarter.
ETF Managers Group sold 10,453 Relay Therapeutics shares in Q1 2023, an estimated $156K.
ETF Managers Group first reported a position in Relay Therapeutics in Q4 2022 and held it in 1 quarter.
ETF Managers Group's Relay Therapeutics position peaked at $156K in Q4 2022.
157 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.